Chi-Chung Li

11PUBLICATIONS
58CO-AUTHORS
Toxicology (incl. clinical toxicology)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Marketing research methodology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jan 28, 2026
Correction: Susilo et al. Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies. Pharmaceutics 2025, 17, 500.

Monica E Susilo, Stephan Schaller, Luis David Jiménez-Franco

|Apr 26, 2025
Whole-Body Physiologically Based Pharmacokinetic Modeling Framework for Tissue Target Engagement of CD3 Bispecific Antibodies.

Monica E Susilo, Stephan Schaller, Luis David Jiménez-Franco

|Apr 25, 2025
Ethnic Sensitivity Assessment of Mosunetuzumab Pharmacokinetics and Pharmacodynamics in Chinese Patients With Relapsed or Refractory Follicular Lymphoma.

Junyi Li, Michael Z Liao, Justin Wilkins

|Nov 18, 2024
Clinical Pharmacology of Cytokine Release Syndrome with T-Cell-Engaging Bispecific Antibodies: Current Insights and Drug Development Strategies.

Kendra K Radtke, Brendan C Bender, Zao Li

|Sep 27, 2024
A Novel Step-Up Dosage Regimen for Enhancing the Benefit-to-Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma.

Chi-Chung Li, Brendan Bender, Justin Wilkins

|May 29, 2024
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.

Brendan Bender, Chi-Chung Li, Mathilde Marchand

Pageof 2

Frequent Collaborators

3 joint publications

Brendan C Bender

3 joint publications

Bei Wang

3 joint publications

Chunze Li

3 joint publications

Michael Wei